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ABSTRACT 1 
Objective: We aimed to determine whether autoantibodies against apolipoprotein A-1 (anti-2 
apoA-1 IgG) predict incident coronary artery disease (CAD), defined as adjudicated incident 3 
myocardial infarction, angina, percutaneous coronary revascularization or bypass grafting, in the 4 
general population. We further investigated whether this association is modulated by a 5 
functional CD14 receptor single-nucleotide polymorphism (SNP). 6 
Approach and Results: In a prospectively-studied, population-based cohort of 5220 subjects 7 
(mean age 52.6 ± 10.7 years, 47.4% males), followed over a median period of 5.6 years, 8 
subjects positive vs. negative for anti-apoA-1 IgG, presented a total CAD rate of 3.9% vs. 2.8% 9 
(p=0.077), and a non-fatal CAD rate of 3.6% vs. 2.3% (p=0.018) respectively. After multivariate 10 
adjustment, the hazard ratio (HR) of anti-apoA-1 IgG were: HR=1.36 [(95% Confidence Intervals 11 
(CI) 0.94–1.97), p=0.105], and HR=1.53 [(95%CI 1.03–2.26), p=0.034], for total and non-fatal 12 
CAD, respectively. In subjects with available genetic data for the C260T rs2569190 SNP in the 13 
CD14 receptor gene (n=4247), we observed a significant interaction between anti-apoA-1 IgG 14 
and rs2569190 allele status with regards to CAD risk, with anti-apoA-1 IgG conferring the 15 
highest risk for total and non-fatal CAD in non-TT carriers, whereas being associated with the 16 
lowest risk for total and non-fatal CAD in TT homozygotes (“p-for-interaction”=0.011 and “p-for 17 
interaction”=0.033 respectively).  18 
Conclusions: Anti-apoA-1 IgG are independent predictors of non-fatal incident CAD in the 19 
general population. The strength of this association is dependent on a functional polymorphism 20 
of the CD14 receptor gene, a finding suggesting a “gene-autoantibody” interaction for the 21 
development of CAD.  22 
 23 
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INTRODUCTION 1 
Major discoveries in the pathophysiology of atherosclerosis have established the fundamental 2 
role of a chronic inflammatory state in the initiation, progression and - finally - rupture of the 3 
atherosclerotic plaque. 1 During the last decade, humoral autoimmunity and autoantibodies 4 
have been recognized as important modulators of vascular inflammation and atherogenesis. 2 5 
Autoantibodies can be active mediators in the development of coronary artery disease (CAD) 3, 4 6 
and as such, serve as biomarkers for the prediction of incident CAD 5-9 and potentially as 7 
biological targets amenable to specific immunomodulatory therapies. 8 
Recently, the atherogenic role of autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG), 9 
the principal protein component of high-density lipoprotein (HDL) has been investigated in 10 
clinical studies, showing that anti-apoA-1 IgG are associated with prevalent and incident CAD in 11 
subjects with autoimmune diseases 5, subjects at high CV risk 6, 10 or following myocardial 12 
infarction 4, 7, independently of established cardiovascular risk factors (CVRFs). Furthermore, we 13 
recently showed that anti-apoA-1 IgG are present in up to one-fifth of individuals in the general 14 
population and independently associated with prevalent CAD 11 as well as with all-cause 15 
mortality 12. Nevertheless, their predictive value for incident CAD in the general population has 16 
not yet been studied. 17 
From a pathophysiological point of view, in vitro and in vivo studies have demonstrated that anti-18 
apoA-1 IgG per se behave as pro-inflammatory, pro-arrhythmogenic and pro-thrombotic 19 
molecules, promoting atherogenesis, myocardial necrosis and death in mice. 4, 13 Based upon 20 
previous published studies, such events could be related to a chronic low-grade inflammatory 21 
state, 3, 14, 15, associations with elevated high-sensitivity C-reactive protein and with increased 22 
uric acid levels, 11 impairment of HDL anti-atherogenic properties, 16-18, interference with basal 23 
heart rate regulation 7, 11, 15 or breakdown of self-tolerance. 12 However, the main 24 
pathophysiological mechanism – reported so far – underpinning the pathogenicity of anti-apoA-1 25 
IgG is their interaction with innate immune system receptors and the activation of the 26 
TLR2/TLR4/CD14 complex. 14, 19 In particular, the current paradigm suggests that, due to 27 
molecular mimicry of the C-terminal part of ApoA-1 to Toll-like receptor (TLR) TLR2, anti-apoA-1 28 
IgG bind to the TLR2/TLR4 complex, and require a functional CD14 receptor for effective 29 
intracellular signaling, NF-κB and MAPK downstream activation, and production of pro-30 
inflammatory cytokines. 13  31 
These findings point to CD14 receptor, the canonical ligand of lipopolysaccharid (LPS), as a 32 
major effector of the anti-apoA-1 IgG deleterious properties. A functional single nucleotide 33 
polymorphism (SNP) at position C260T (rs2569190) of the CD14 receptor gene has been 34 
shown to modulate its transcriptional activity. 20, 21 Among the three groups of CD14 genotypes 35 
for rs2569190 (CC, CT or TT), TT carriers appear to be protected from CD14 ligand-induced 36 
inflammation due to a better ability to adequately control the LPS-mediated TLR/CD14–37 
dependent immune response. 22-24 Indeed, previous studies demonstrated that TT carriers were 38 
less at risk for Gram-negative bacterial infection and sepsis death, 25, 26 for developing heart 39 
failure, 27 as well as atherosclerosis, 28-30 although this latter observation is debated. 31 However, 40 
whether TT carriers are also less susceptible to anti-apoA-1 IgG-related atherosclerosis has not 41 
been examined. 42 
Thus, our current study had two main aims: firstly, we investigated whether anti-apoA-1 IgG 43 
predict incident CAD in the general population. Secondly, because of anti-apoA-1 IgG role as a 44 
danger-associated molecular pattern (DAMP), specifically activating CD14-related pathways 4, 45 
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13, we further examined whether the functional C260T rs2569190 polymorphism in the CD14 1 
receptor gene modulates the anti-apoA-1 IgG-related CAD risk, hypothesizing a protective effect 2 
associated with carriage of the T allele.  3 
 4 
MATERIALS AND METHODS 5 
Materials and Methods, including characterization analyses related to anti-apoA-1 IgG assay 6 
validation are available in the online-only Data Supplement. 7 
 8 
RESULTS 9 
Association between anti-apoA-1 IgG and incident CAD 10 
Figure 1 demonstrates the flowchart of the study. Of the initial 6733 participants, 5220 had 11 
complete clinical and biological data over a median follow-up (FU) time of 5.6 years and were 12 
included in the final sample. Participants that did not participate in FU (21.6%) were more likely 13 
to be smokers, hypertensive, overweight with a less favorable lipid profile, compared to those 14 
included in the analysis. There were no significant differences in anti-apoA-1 IgG levels or 15 
prevalence of anti-apoA-1 IgG positivity between the two groups (Supplementary Table I).  16 
Table 1 provides baseline characteristics of the final sample according to anti-apoA-1 IgG 17 
status. Overall, CVRFs were equally distributed between subjects with positive vs. negative anti-18 
apoA-1 IgG titers. Among the 157 subjects who developed CAD during FU, 132 had a non-fatal 19 
event, and 25 a fatal one. Total Incident CAD rate was 3.9% vs. 2.8% (p=0.077), while non-fatal 20 
incident CAD rate was 3.6% vs. 2.3% (p=0.018) for subjects with positive vs. negative anti-21 
apoA-1 IgG titers. No significant differences were observed with regards to fatal incident CAD. 22 
Table 2 summarizes hazard ratios (HR) for the association of anti-apoA-1 IgG with total, non-23 
fatal and fatal incident CAD. In unadjusted models, we retrieved a trend between anti-apoA-1 24 
IgG positivity and total incident CAD (HR: 1.39, 95% Confidence Intervals (CI): 0.97–1.99, 25 
p=0.073), that remained unchanged after adjusting for sex, age, smoking status, diabetes, 26 
systolic blood pressure (SBP), LDL and HDL cholesterol, baseline CAD, statin and beta-blocker 27 
treatment, and estimated glomerular filtration rate (eGFR) (HR: 1.36, 95%CI: 0.94–1.97, 28 
p=0.105). The HRs of one SD increase in log-transformed anti-apoA-1 IgG values for total 29 
incident CAD were HR: 1.11, 95%CI: 0.96–1.28 (p=0.159), and HR: 1.09, 95%CI: 0.94–1.27 30 
(p=0.232), in the unadjusted and adjusted analysis respectively. Levels of anti-apoA-1 IgG 31 
above OD>0.98 (3rd tertile) were significantly associated with total incident CAD in the 32 
unadjusted (HR 1.79, 95%CI 1.09–2.95, p=0.021) and the adjusted analysis (HR: 1.70, 95%CI: 33 
1.03–2.81, p=0.038). 34 
Furthermore, anti-apoA-1 IgG positivity was significantly associated with non-fatal incident CAD 35 
both in the unadjusted (HR: 1.58, 95%CI 1.08–2.31, p=0.018) and the adjusted analysis (HR: 36 
1.53, 95%CI 1.03–2.26, p=0.034). Similarly to what was observed for total incident CAD, the 37 
HRs of one SD increase in log-transformed anti-apoA-1 IgG values for non-fatal CAD were: HR: 38 
1.15, 95%CI 0.99–1.34, (p=0.072), and HR: 1.14, 95%CI: 0.97–1.33 (p=0.109), in the 39 
unadjusted and adjusted analysis respectively. Anti-apoA-1 IgG levels above OD>0.98 (3rd 40 
tertile) were strongly associated with non-fatal incident CAD both in the unadjusted (HR: 2.21, 41 
95%CI 1.34–3.67, p=0.002) and the adjusted model (HR: 2.14, 95%CI 1.29–3.56, p=0.003) 42 
(Table 2). On the other hand, no associations were observed between anti-apoA-1 IgG positivity 43 
or tertiles with fatal incident CAD. Sensitivity analyses after exclusion of subjects with baseline 44 
CAD or autoimmune disease yielded similar results for the associations between anti-apoA-1 45 
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IgG and total, non-fatal and fatal CAD (Supplementary Table II). Additionally, statistical 1 
analyses after excluding adjustment for statin and beta-blocker treatment, or eGFR from the 2 
fully adjusted model yielded similar results (Supplementary Table, III). 3 
 4 
Interaction between C260T rs2569190 polymorphism and anti-apoA-1 IgG for incident 5 
CAD 6 
Among genotyped subjects (n=4247, Figure 1), we further investigated whether the functional 7 
C260T rs2569190 polymorphism in the CD14 receptor gene modulates anti-apoA-1 IgG-related 8 
CAD risk. Subjects with missing genetic data tended to have a lower burden of CVRFs and a 9 
higher prevalence of anti-apoA-1 IgG positivity (Supplementary Tables IV & V).  10 
Characteristics of the genotyped sample, according to the C260T rs2569190 polymorphism 11 
allele status are illustrated in Supplementary Table VI. All CVRFs were equally distributed 12 
among subgroups, with the exception of an increased prevalence of diabetes and statin 13 
treatment in the TT subgroup. Importantly, the C260T rs2569190 polymorphism per se was not 14 
associated with total, non-fatal or fatal incident CAD, all-cause mortality or anti-apoA-1 IgG 15 
positivity (Supplementary Table VI). 16 
In order to assess differences in anti-apoA-1 IgG-related CAD risk according to the C260T 17 
rs2569190 polymorphism, we created both an additive (CC vs. CT vs. TT) as well as a 18 
recessive (CC/CT vs. TT) model and performed a statistical test for the interaction 32 between 19 
anti-apoA-1 IgG and carriage of the T allele, for total and non-fatal incident CAD risk. As 20 
previously, all analyses were adjusted for sex, age, smoking status, diabetes, SBP, LDL and 21 
HDL cholesterol, baseline CAD, statin and beta-blocker treatment and eGFR. 22 
In the case of the additive model (CC vs. CT vs. TT), we observed a gradient of risk for anti-23 
apoA-1 IgG with regards to CAD across the three predefined C260T rs2569190 subgroups 24 
(Table 3). Specifically, in the subgroup homozygote for the major allele (CC, n=1097), the 25 
adjusted anti-apoA-1 IgG HR for total CAD was HR: 2.27; 95%CI: 1.04–4.97, (p=0.039), while it 26 
was HR: 1.52; 95%CI: 0.86–2.71, (p=0.152) in the heterozygote subgroup (CT, n=2095), and 27 
HR: 0.55; 95%CI: 0.19–1.61, (p=0.275) in the minor allele subgroup (TT, n=1055). Results were 28 
similar with regards to the recessive (CC/CT vs. TT) model. Notably, in non-TT carriers – 29 
representing 75.1% of the cohort, anti-apoA-1 IgG positivity conferred a 1.8-fold risk for total 30 
CAD (HR 1.77; 95%CI 1.12–2.80, p=0.014, Table 3), while change per 1SD in anti-apoA-1 31 
values yielded a HR of 1.11; 95%CI 0.92–1.34 (p=0.285) for total CAD, in the fully adjusted 32 
model. Results were similar with regards to non-fatal incident CAD (Table 3).  33 
Testing for the interaction between anti-apoA-1 IgG and C260T rs2569190 polymorphism with 34 
respect to CAD in a fully adjusted analysis, indicated that the observed gradient in anti-apoA-1 35 
IgG-related CAD risk across the different CD14 genotype subgroups in the additive (CC vs. CT 36 
vs. TT) model was statistically significant, for both total and non-fatal CAD risk (“p-for-37 
interaction”=0.011, and “p-for-interaction”=0.033, respectively; Table 3), proving substantial 38 
heterogeneity in anti-apoA-1 IgG-related CAD risk according to T allele carriage. A forest plot 39 
summarizes these findings (Supplementary Figure 1). Furthermore, statistical analyses after 40 
excluding adjustment for statin and beta-blocker treatment, or eGFR from the fully adjusted 41 
model yielded similar results (Supplementary Table, VII). 42 
Figure 2 describes Kaplan-Meier curves for total and non-fatal CAD according to anti-apoA-1 43 
IgG positivity and C260T rs2569190 allele status. Participants positive for anti-apoA-1 IgG 44 
(panels A and B) presented an increased risk for total and non-fatal CAD compared to those 45 
negative for anti-apoA-1 IgG. After splitting the positive anti-apoA-1 IgG group according to 46 
homozygous or not carriage of the T allele (CC/CT vs. TT), a decrease in the proportion of total 47 
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and non-fatal CAD was observed in the anti-apoA-1 IgG positive TT subgroup (panels C and D, 1 
green line), falling below the rate of CAD observed in anti-apoA-1 IgG negative subjects (panels 2 
C and D, blue line). Conversely, higher proportion of total and non-fatal CAD was observed in 3 
anti-apoA-1 IgG positive non-TT carriers (panels C and D, black line), when compared to anti-4 
apoA-1 IgG positive subjects as a whole (panels C and D red line, log-rank: p=0.023, and 5 
p=0.017, for total and non-fatal CAD respectively).  6 
7 
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DISCUSSION 1 
The main finding of the present study is that anti-apoA-1 IgG are independently associated with 2 
non-fatal incident CAD in the general population, with the anti-apoA-1 IgG-related CAD risk 3 
being strongly modulated by the C260T rs2569190 CD14 gene polymorphism. Indeed, after 4 
taking CD14 SNPs into account, we observed a significant anti-apoA-1 IgG-related CAD risk 5 
gradient, dependent on carriage of the C260T rs2569190 T allele, with non-TT carriers being at 6 
significantly increased risk for both total and non-fatal CAD compared to TT homozygotes. Our 7 
results extend current knowledge not only in the field of anti-apoA-1 IgG, but also in the field of 8 
personalized CAD prediction in different ways.  9 
Firstly, similarly to what has been shown in high risk populations, 5-7, 33, our current findings 10 
argue that anti-apoA-1 IgG positivity is an independent predictor of poor CV outcome in the 11 
general population, supporting the notion that preclinical autoimmunity to apolipoprotein A-1 12 
may identify a substantial proportion of individuals at increased risk of CAD. In our study, anti-13 
apoA-1 IgG-related CAD risk was highest in subjects carrying at least one C allele  (CC/CT) in 14 
the functional C260T rs2569190 polymorphism, a group that represents roughly three quarters 15 
of Caucasian populations. 31 By virtue of being the first study on a “gene-autoantibody” 16 
interaction with respect to CAD, our analysis highlights the importance of incorporating genetic 17 
data on immune-related polymorphisms when evaluating anti-apoA-1 IgG-related risk and 18 
provides insight for future study design on personalized CAD prediction. 19 
Secondly, these results represent a human validation of the key role of CD14 co-receptor in 20 
mediating the anti-apoA-1 IgG pro-atherogenic properties as demonstrated so far in animal and 21 
in vitro models, 4, 13 and reinforce the relevance of these preclinical results to the anti-apoA-1 22 
IgG-associated CAD risk in humans. Conversely, in line with a recent meta-analysis, 31 our 23 
findings are equivocal and do not provide definite evidence with regards to the association 24 
between TT genotype carriage and CAD risk.  25 
Thirdly, our data highlight the importance of considering the individual genetic information on 26 
innate immune receptors for proper assessment of CAD risk associated to biomarkers of 27 
humoral autoimmunity. To the best of our knowledge, none of the genetic studies published so 28 
far took into account biomarkers (including autoantibodies) for CAD risk prediction, and none of 29 
the publications exploring the auto-antibodies-associated CAD risk prediction evaluated the 30 
impact of individual genetic background on such risk. By demonstrating a potentially important 31 
gene-environment interaction between anti-apoA-1 IgG and the CD14 receptor gene in the 32 
pathogenesis of atherosclerosis, our findings may explain the discordant findings regarding both 33 
the role of CD14 polymorphisms in CAD risk, 31 and the contrasting results of humoral auto-34 
autoimmunity in CAD risk assessment. 33 Overall, our results provide a “proof-of-concept” that 35 
combining genetic data together with serum biomarkers is likely to be required for the 36 
implementation of precision medicine in the field of CAD prediction.  37 
In our study, the fact that TT carriers were less at risk to develop anti-apoA-1 IgG-related CAD 38 
compared to non-TT carriers, despite TT homozygote status being previously associated with a 39 
higher systemic inflammatory profile, 20, 21 merits mention. To this respect, several lines of 40 
evidence indicate that TT genotype could confer protection against uncontrolled inflammatory 41 
response evoked by long-term DAMP exposure through different and mutually non-exclusive 42 
mechanisms. Firstly, previous studies indicate that in the context of chronic low grade 43 
CD14/TLR4 stimulation, the higher levels of sCD14 ascribed to TT genotype inhibit systemic 44 
LPS-mediated inflammatory responses by down-regulating inflammatory cytokines transcription 45 
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34, 35, and facilitating CD14-related DAMP clearance 24, thus protecting TT carriers against 1 
sustained inflammatory responses, through a negative feedback mechanism. Inversely, lower 2 
levels of sCD14 observed in CC carriers have been shown to favor vascular wall inflammation 3 
and atherogenesis through impaired plasma clearance of endotoxin. 22, 23 C-allele carriers may 4 
be less able to prevent anti-apoA-1 IgG-mediated CD14/TLR4 activation, resulting in 5 
maintenance of a pro-atherogenic state and a higher risk for developing CAD. 28-30 Lastly, 6 
increased expression of CD14 on the vascular endothelium of TT homozygotes 35 could also 7 
play a role in atherogenesis, in response to CD14 ligands such as anti apoA-1 IgG. 22, 23, 34, 35 8 
Several study limitations are noteworthy. Firstly, although great effort was undertaken to 9 
maximize the participation rate during follow-up, our results may be subject to attrition bias as 10 
drop out rate after mean duration of 5.6 years was about ~20%. Nevertheless, similar losses in 11 
follow up are commonly reported in prospective cohorts 36 and are within the conventional 12 
participation rate thresholds for cohort studies. 37 Secondly, we didn’t directly measure sCD14 in 13 
study subjects, in order to confirm the presumed higher sCD14 levels in TT homozygote carriers 14 
reported previously. Moreover, as our assay assesses anti-apoA-1 IgG antibodies against 15 
native apoA-1, 19, 38 we were not able to measure antibodies against modified forms of apoA-1, 16 
such as oxidized apoA-1 (or possibly glycated and carbamylated apoA-1). As these modified 17 
forms of apoA-1 were shown to be of relevance for HDL functionality and the pathology of 18 
atherosclerosis, 39-41 knowing whether they would elicit a humoral response clinically relevant to 19 
human physiopathology is still unclear. Thirdly, due to sample availability, we only measured 20 
baseline anti-apoA-1 IgG levels and did not assess the dynamic of anti-apoA-1 IgG levels over 21 
time in relation with incident CAD. Moreover, we could not test other clinically relevant 22 
antibodies, such as anti-oxidized LDL, anti-phospholipid, anti-nuclear or anti-heat shock protein 23 
antibodies, which would have been instrumental to better understanding potential associations 24 
with innate immune receptor-related genes of interest. Finally, sample size calculation in our 25 
study was performed with regards to the primary outcome of detecting a difference in incident 26 
CAD in subjects positive vs. negative for anti-apoA-1 IgG. Although the fact that previous 27 
evidence suggested an interaction between anti-apoA-1 IgG and the CD14 receptor and that we 28 
were able to detect such a – significant – interaction between anti-apoA-1 IgG and the functional 29 
C260T rs2569190 polymorphism in the CD14 receptor gene, it is possible that the current 30 
sample size provided less than 80% power for this secondary study outcome. Therefore, this 31 
finding of our study requires replication in larger prospective studies. 32 
In conclusion, anti-apoA-1 IgG levels are independent predictors of incident non-fatal CAD in 33 
the general population. The strength of this association is significantly modulated by the 34 
functional C260T rs2569190 SNP in the CD14 receptor gene, being the highest in non-TT 35 
carriers and the lowest in TT homozygotes. These results imply that preclinical autoimmunity to 36 
apolipoprotein A-1 should be evaluated carefully as it may help to improve the identification of 37 
individuals at increased risk of CAD in the general population, especially in non-TT carriers 38 
representing up to 75% of the population. Our findings indicate that “gene-autoantibodies” 39 
interaction studies are likely to be required to better assess the CAD risk related to humoral 40 
autoimmunity biomarkers in the general population, a concept that requires further investigation 41 
in future studies. 42 
43 
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 1 
Highlights 2 
• Anti-apoA-1 IgG are independent predictors of non-fatal incident coronary artery 3 
disease in the general population. 4 
• Anti-apoA-1 IgG could represent a potential novel target for immune-modulating 5 
preventive strategies for coronary artery disease. 6 
• The strength of the association between anti-apoA-1 IgG and coronary artery 7 
disease is dependent on a functional polymorphism of the CD14 receptor gene. 8 
• Our findings suggesting a “gene-autoantibody” interaction for the development of 9 
CAD, an observation that requires further study.   10 
11 
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 1 
FIGURE LEGENDS 2 
Figure 1: Study flowchart 3 
Anti-apoA-1 IgG; autoantibodies against Apolipoprotein A-1, CAD; Coronary Artery Disease 4 
 5 
Figure 2: Kaplan-Meier curves for cumulative incident coronary artery disease. 6 
Above, Kaplan-Meier curves for cumulative (A) total and (B) non-fatal incident CAD according to 7 
anti-apoA-1 IgG status (red line, positive for anti-apoA-1 IgG; blue line, negative for anti-apoA-1 8 
IgG). Below, Kaplan-Meier curves for cumulative (C) total and (D) non-fatal incident CAD 9 
according to anti-apoA-1 IgG and C260T rs2569190 allele status (black line, positive for anti-10 
apoA-1 IgG and carrying the C allele (CC/CT); green line, positive for anti-apoA-1 IgG and 11 
carrying the T allele (TT); blue line, negative for anti-apoA-1 IgG). Data are expressed as the 12 
cumulative proportion of the sample presenting with incident CAD (y axis) during study years (x 13 
axis). Statistical analysis by Logrank test, for the comparison between anti-apoA-1 IgG negative 14 
subjects (blue line) vs. anti-apoA-1 IgG positive-TT carriers (green line) vs. anti-apoA-1 IgG 15 
positive-non-TT carriers (black line). 16 
Anti-apoA-1 IgG; autoantibodies against Apolipoprotein A-1, CAD; coronary artery disease 17 
 18 
 19 
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 21 
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Table 1: Characteristics of the sample, according to anti-apoA-1 IgG status. 1 
Total sample 
(n=5220) 
Anti-apoA-1 IgG p-value 
Absence (n=4180) Presence (n=1040) 
Age, years 52.7 ± 10.7 52.2 ± 10.7 0.184 
Male sex, n (%) 1985 (47.5) 488 (46.9) 0.744 
History of CAD, n (%) 146 (3.5) 43 (4.1) 0.321 
Current smoking, n (%) 1086 (26.0) 272 (26.2) 0.909 
Diabetes, n (%) 276 (6.6) 58 (5.6) 0.226 
Hypertension, n (%) 1389 (33.23) 349 (33.6) 0.841 
Autoimmune disease, n (%) 88 (2.1) 32 (3.1) 0.061 
Body mass index (kg/m2) 25.6 ± 4.4 25.7 ± 4.6 0.712 
Total cholesterol (mmol/l) 5.58 ± 1.02 5.50 ± 1.03 0.022 
HDL cholesterol (mmol/l)  1.64 ± 0.43 1.62 ± 0.46 0.250 
LDL cholesterol (mmol/l) 3.33 ± 0.90 3.27 ± 0.92 0.068 
Triglycerides (mmol/l) 1.38 ± 1.12 1.36 ± 1.22 0.663* 
SCORE CV risk categories, n 
(%) 
   
Low risk 2507 (60.1) 643 (62.0)  
Intermediate risk 1160 (27.8) 269 (25.9)  
High risk 311 (7.4) 83 (8.0)  
Very high risk 196 (4.7) 43 (4.1) 0.487 
CV drugs, n (%)    
Aspirin 684 (16.4) 160 (15.4) 0.443 
Statins 446 (10.7) 98 (9.4) 0.239 
Beta blockers 212 (5.1) 70 (6.7) 0.034 
  
19 
Calcium channel blockers 120 (2.9) 33 (3.2) 0.605 
ACEi/ARB 511 (12.2) 124 (11.9) 0.354 
Diuretics 80 (1.9) 19 (1.8) 0.854 
Incident CAD rates, n (%) 117 (2.8) 40 (3.9) 0.077 
Non-fatal, n (%) 95 (2.3) 37 (3.6) 0.018 
Fatal, n (%) 22 (0.5) 3 (0.3) 0.320 
Data are expressed as mean ± standard deviation or number of participants and (percentage).  1 
Anti-apoA-1 IgG, anti-apolipoprotein A-1 autoantibodies; CAD, coronary artery disease; HDL, 2 
high density lipoprotein; LDL, low density lipoprotein; SCORE, Systematic Coronary Risk 3 
Evaluation; CV, cardiovascular; ACEi, Angiotensin Converting Enzyme inhibitor; ARB, 4 
Angiotensin Receptor Blockers. Statistical analysis for continuous variables by student’s t-test or 5 
Mann-Whitney test (*) depending on the normality assumption. Statistical analysis for 6 
continuous variables by the chi-squared test. 7 
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Table 2: Hazard Ratios of anti-apoA-1 IgG for incident total, non-fatal and fatal CAD in the general population 
n=5220 Total Incident CAD (n=159) Non Fatal Incident CAD (n=134) Fatal Incident CAD (n=25) 
Unadjusted 
Model 
p-
value 
Adjusted 
Model 
p-
value 
Unadjuste
d Model 
p-
value 
Adjusted 
Model 
p-
value 
Unadjuste
d Model 
p-
value 
Adjusted 
Model 
p-
value 
Positive vs. 
negative  
1.39 
(0.97–1.99) 
0.07
3 
1.36 
(0.94–1.97) 
0.105 1.58 
(1.08–2.31) 
0.018 1.53 
(1.03–2.26) 
0.034 0.54 
(0.16–1.80) 
0.313 0.56 
(0.17–1.91) 
0.356 
1 SD change in 
log-transformed 
anti-ApoA-1 IgG 
levels 
1.11 
(0.96–1.28) 
0.15
9 
1.09 
(0.94–1.27) 
0.232 1.15 
(0.99–1.34) 
0.072 1.14 
(0.97–1.33) 
0.109 0.88 
(0.61–1.29) 
0.520 0.87 
(0.60–1.27) 
0.474 
Anti-ApoA-1 IgG 
levels * 
            
Negative 
(OD<0.64) 
1 
(ref.) 
 1 
(ref.) 
 1 
(ref.) 
 1 
(ref.) 
 1 
(ref.) 
 1 
(ref.) 
 
1st tertile 
(0.64<OD≤0.77) 
1.18 
(0.64–2.19) 
0.59
7 
1.39 
(0.74–2.59) 
0.879 1.32 
(0.69–2.53) 
0.406 1.50 
(0.78–2.89) 
0.227 0.60 
(0.08–4.43) 
0.613 0.75 
(0.96–5.92) 
0.788 
2nd tertile 
(0.77<OD≤0.98) 
1.16 
(0.63–2.16) 
0.63
3 
0.95 
(0.48–1.88) 
0.879 1.17 
(0.59–2.33) 
0.646 0.89 
(0.41–1.93) 
0.767 1.02 
(0.24–4.37) 
0.974 1.13 
(0.26–4.90) 
0.872 
3rd tertile 
(OD>0.98) 
1.79 
(1.09–2.95) 
0.02
1 
1.70 
(1.03–2.81) 
0.038 2.21 
(1.34–3.67) 
0.002 2.14 
(1.29–3.56) 
0.003 no subjects . no subjects . 
P-value for linear 
trend 
0.047  0.160  0.012   0.021 .  .  
 
Results are expressed as adjusted hazard ratios and (95% confidence interval) for subjects positive (OD>0.64) vs. 
negative (OD<0.64) for anti apoA-1 IgG. Statistical analysis by Cox proportional hazards regression adjusted for age, 
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sex, systolic blood pressure, diabetes, smoking, HDL and LDL cholesterol, baseline CAD, statin, beta-blocker treatment 
and eGFR. CAD, coronary artery disease; Anti-apoA-1 IgG, anti-apolipoprotein A-1 autoantibodies; SD, standard 
deviation; OD, optical density; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated Glomerular 
Filtration Rate.  
* Subjects with positive Anti-ApoA-1 (n=1040) were divided in tertiles (n=347) of increasing titers: 1st tertile (0.64<OD<0.77), 
2nd tertile (0.77<OD<0.98) and 3rd tertile (OD>0.98). 
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Table 3: Hazard Ratios of anti-apoA-1 IgG for incident total, non-fatal and fatal CAD according to the C260T rs2569190 
polymorphism allele status, in the genotyped population 
Anti-apoA-1 IgG 
HR (95% CI) 
for CAD 
Total Incident CAD (n= 132) Non Fatal Incident CAD (n= 109) Fatal Incident CAD (n= 23) 
C260T rs2569190 
allele status 
Unadjusted 
Model 
p-
value 
Adjusted 
Model 
p-
value 
Unadjuste
d Model 
p-
value 
Adjusted 
Model 
p-
value 
Unadjuste
d Model 
p-
value 
Adjusted 
Model 
p-
value 
CC (n=1097) 2.08 
(0.98; 4.42) 
0.056 2.27 
(1.04; 4.97) 
0.039 2.19 
(0.98; 4.87) 
0.055 2.38 
(1.03; 5.51) 
0.042 1.39 
(0.14; 
13.42) 
0.773 1.55 
(0.15; 
15.81) 
0.713 
CC/CT (n=3192) 1.67 
(1.07; 2.60) 
0.023 1.77 
(1.12; 2.80) 
0.014 1.84 
(1.14; 2.95) 
0.012 1.95 
(1.19; 3.19) 
0.008 0.91 
(0.26; 3.17) 
0.880 0.90 
(0.24; 3.32) 
0.877 
CT (n=2095) 1.55 
(0.89; 2.68) 
0.120 1.52 
(0.86; 2.71) 
0.152 1.75 
(0.96; 3.16) 
0.066 1.73 
(0.93; 3.23) 
0.084 0.76 
(0.17; 3.43) 
0.718 0.54 
(0.10; 3.00) 
0.486 
TT (n=1055) 0.58 
(0.20; 1.65) 
0.306 0.55 
(0.19; 1.61) 
0.275 0.74 
(0.25; 2.14) 
0.573 0.74 
(0.25; 2.22) 
0.592 no subjects  no subjects  
P-value for 
interaction 
between anti-
apoA-1 IgG & 
rs2569190 
(CC vs. CT vs. TT) 
 0.064  0.011  0.135  0.033  n/a  n/a 
P-value for 
interaction 
between anti-
apoA-1 IgG & 
 0.068  0.020  0.126  0.047  n/a  n/a 
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rs2569190 
(CC/CT vs. TT) 
Results are expressed as adjusted hazard ratios and (95% confidence interval) for subjects positive (OD>0.64) vs. 
negative (OD<0.64) for anti apoA-1 IgG. Statistical analysis by Cox proportional hazards regression adjusted for age, 
sex, systolic blood pressure, diabetes, smoking, HDL and LDL cholesterol, baseline CAD, statin, beta-blocker treatment 
and eGFR. The P value for interaction represents the likelihood of interaction between the C260T rs2569190 allele 
status and the relative anti-apoA-1 IgG effect for coronary artery disease. 
CAD, coronary artery disease; Anti-apoA-1 IgG, anti-apolipoprotein A-1 autoantibodies; HR, hazard ratio; CI, confidence 
interval; OD, optical density; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated Glomerular 
Filtration Rate.  
 
Baseline sample
n= 6733 (100%)
Non-Caucasian, 
n= 395 (5.9%)
Missing genetic data,
n= 578 (8.6%)
Final sample
n= 5220 (77.5%)
Genotyped Sample
n= 4247 (63.1%)
Did not participate in FU, n= 1456 (21.6%)
483  refused due to an unkown reason
347  refused due to a logistic reason
226  were lost to FU
221  were unable to participate due to
relocation from the city
179  withdraw consent to participate in FU
Missing anti-apoA-1 IgG
measurements, n=57 (0.8%)
n= 6676 (99.2%)
Primary Endpoint:
• Incident total CAD
Secondary Endpoints:
• Incident non-fatal CAD
• Incident fatal CAD
Interaction between anti-apoA-1
IgG & the C260T rs2569190
polymorphism in the CD14
receptor gene, with regards to
incident CAD risk
Log-rank p=0.072 Log-rank p=0.021
Association between anti-apoA-1 IgG and 
non-fatal incident CAD
Association between anti-apoA-1 IgG and 
total incident CAD
Negative 
anti-apoA-1 IgG
Positive
anti-apoA-1 IgG
Negative 
anti-apoA-1 IgG
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anti-apoA-1 IgG 
&
CC/CT in rs2569
190
Positive
anti-apoA-1 IgG
Association between anti-apoA-1 IgG and non-fatal
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Positive
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TT in rs2569190
Association between anti-apoA-1 IgG and total
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Negative 
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Positive
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Negative 
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Positive
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Log-rank p=0.072 Log-rank p=0.021
Association between anti-apoA-1 IgG and 
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Positive
anti-apoA-1 IgG
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&
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Positive
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Positive
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Association between anti-apoA-1 IgG and total
incident CAD, according to rs2569190 allele status
P-for-interaction=0.011 P-for-interaction=0.033
Negative 
anti-apoA-1 IgG
Positive
anti-apoA-1 IgG &
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Negative 
anti-apoA-1 IgG
Positive
anti-apoA-1 IgG &
TT in rs2569190
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Supplemental Table I: Baseline characteristics of subjects included in the analysis vs. subjects missing follow-
up data. 
Overall sample 
(n=6676) 
Subjects included in the 
analysis 
(n=5220) 
Subjects missing follow-
up data 
(n=1456) 
p-value 
Age, years 52.6 ±10.7 52.6 ± 10.8 0.979 
Male sex, n (%) 2496 (47.3) 693 (47.6) 0.841 
History of CVD, n (%) 398 (7.5) 90 (6.2) 0.076 
Current smoking, n (%) 1382 (26.2) 430 (29.5) 0.011 
Diabetes, n (%) 336 (6.4) 100 (6.9) 0.492 
Hypertension, n (%) 1756 (33.3) 579 (39.8) <0.001 
Body mass index (kg/m2) 25.65 ± 4.41 26.34 ± 4.85 <0.001 
Total cholesterol (mmol/l) 5.56 ± 1.02 5.62 ± 1.10 0.093 
HDL cholesterol (mmol/l)  1.64 ± 0.44 1.60 ± 0.43 0.006 
LDL cholesterol (mmol/l) 3.32 ± 0.90 3.37 ± 0.95 0.038 
Triglycerides (mmol/l) 1.37 ± 1.14 1.46 ± 1.31 0.010* 
SCORE CV risk categories, n (%) 2.07 ± 3.56 2.13 ± 3.40 0.145* 
Low risk 3150 (60.4) 817 (57.3)  
Intermediate risk 1429 (27.4) 421 (29.5)  
High risk 394 (7.6) 119 (8.3)  
Very high risk 239 (4.6) 70 (4.9) 0.189 
Anti-apoA-1 IgG, n (%) 1040 (19.9) 283 (19.8) 0.920 
Anti-apoA-1 OD 0.46 ± 0.33 0.45 ± 0.36 0.377* 
3 
 
 
Data are expressed as mean ± standard deviation or number of participants and (percentage). CVD, 
cardiovascular disease; SBP, systolic blood pressure; HDL, high density lipoprotein; LDL, low density 
lipoprotein; SCORE, Systematic Coronary Risk Evaluation; Anti-apoA-1 IgG, anti-apolipoprotein A-1 
autoantibodies; OD, Optical Density. Statistical analysis for continuous variables by student’s t-test or 
Mann-Whitney test (*) depending on the normality assumption. Statistical analysis for categorical 
variables by the chi-squared test. 
4 
 
Supplemental Table II: Hazard Ratios of anti-apoA-1 IgG for incident total, non fatal and fatal coronary 
artery disease in the general population, after excluding subjects with a) baseline coronary artery disease, 
b) baseline autoimmune disease. 
Hazard Ratios (95% CI) Incident CAD (n=111) Non Fatal Incident CAD (n=93) Fatal Incident CAD (n=18) 
a) Excluding subjects 
with baseline 
coronary artery 
disease (n=5031) 
Unadjusted 
Model  
p-
value 
Adjusted 
Model 
p-
value 
Unadjusted 
Model  
p-
value 
Adjusted 
Model 
p-
value 
Unadjusted 
Model  
p-
value 
Adjusted 
Model 
p-
value 
Positive vs. negative 
anti-ApoA-1 IgG 
1.44 (0.94–
2.20) 
0.093 1.54 (1.00–
2.38) 
0.050 1.57 (1.00–
2.48) 
0.050 1.69 (1.06–
2.68) 
0.027 0.79 (0.23–
2.75) 
0.717 0.90 (0.26–
3.15) 
0.868 
Hazard Ratios (95% CI) Incident CAD (n=148) Non Fatal Incident CAD (n=124) Fatal Incident CAD (n=24) 
b) Excluding subjects 
with baseline 
autoimmune disease 
(n=5100) 
Unadjusted 
Model  
p-
value 
Adjusted 
Model 
p-
value 
Unadjusted 
Model  
p-
value 
Adjusted 
Model 
p-
value 
Unadjusted 
Model  
p-
value 
Adjusted 
Model 
p-
value 
Positive vs. negative 
anti-ApoA-1 IgG 
1.37 (0.95–
1.99) 
0.095 1.42 (0.98–
2.08) 
0.077 1.62 (1.10–
2.40) 
0.015 1.64 (1.11–
2.46) 
0.017 0.36 (0.09–
1.55) 
0.172 0.43 (0.12–
1.86) 
0.256 
 
Results are expressed as adjusted hazard ratios (95% confidence interval). Statistical analysis by Cox 
proportional hazards regression adjusted for age, sex, systolic blood pressure, diabetes, smoking, 
HDL cholesterol and LDL cholesterol, statin, beta-blocker treatment and eGFR. CAD, coronary artery 
disease; OD, optical density; Anti-apoA-1 IgG, anti-apolipoprotein A-1 autoantibodies; eGFR, 
estimated glomerular filtration rate 
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Supplementary Table III: Hazard Ratios of anti-apoA-1 IgG for incident total, non-fatal and 
fatal CAD in the general population. 
Final sample 
(n=5220) 
Total Incident CAD (n=159) Non Fatal Incident CAD (n=134) Fatal Incident CAD (n=25) 
Adjusted 
Model_1 
p-
value 
Adjusted 
Model_2 
p-
value 
Adjusted 
Model_1 
p-
value 
Adjusted 
Model_2 
p-
value 
Adjusted 
Model_1 
p-
value 
Adjusted 
Model_2 
p-
value 
Positive vs. negative  1.36 (0.94–
1.97) 
0.099 1.37 (0.94–
1.98) 
0.100 1.53 (1.03–
2.26) 
0.034 1.54 (1.04–
2.28) 
0.031 0.58 (0.17–
1.98) 
0.387 0.56 (0.17–
1.91) 
0.355 
1 SD change in log-
transformed anti-
ApoA-1 IgG levels 
1.08 (0.94–
1.25) 
0.265 1.09 (0.94–
1.26) 
0.251 1.12 (0.96–
1.30) 
0.144 1.13 (0.97–
1.32) 
0.121 0.89 (0.62–
1.29) 
0.541 0.87 (0.60–
1.28) 
0.479 
Anti-ApoA-1 IgG 
levels * 
            
Negative 
(OD<0.64) 
1 
(ref.) 
 1 
(ref.) 
 1 
(ref.) 
 1 
(ref.) 
 1 
(ref.) 
 1 
(ref.) 
 
1st tertile 
(0.64<OD≤0.77) 
1.45 (0.78–
2.69) 
0.243 1.45 (0.78–
2.71) 
0.237 1.57 (0.82–
3.01) 
0.177 1.58 (0.82–
3.04) 
0.168 0.75 (0.10–
5.66) 
0.780 0.69 (0.09–
5.30) 
0.718 
2nd tertile 
(0.77<OD≤0.98) 
1.02 (0.52–
2.01) 
0.958 0.95 (0.48–
1.88) 
0.882 0.96 (0.44–
2.07) 
0.910 0.89 (0.41–
1.93) 
0.766 1.16 (0.27–
5.05) 
0.839 1.12 (0.26–
4.86) 
0.880 
3rd tertile 
(OD>0.98) 
1.58 (0.96–
2.60) 
0.074 1.66 (1.01–
2.75) 
0.047 1.95 (1.17–
3.23) 
0.010 2.10 (1.26–
3.49) 
0.004 no subjects . no subjects . 
P-value for linear 
trend 
 0.254  0.167  0.103  0.022  .  . 
 
Results are expressed as adjusted hazard ratios and (95% confidence interval) for the positive 
(OD>0.64) vs. negative (OD<0.64) anti apoA-1 antibodies. Statistical analysis by Cox proportional 
hazards regression adjusted for age, sex, hypertension, diabetes, smoking, HDL cholesterol and LDL 
cholesterol, baseline CAD, (Adjusted Model_1) statin, beta-blocker treatment (Adjusted Model_2). 
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CAD, coronary artery disease; Anti-apoA-1 IgG, anti-apolipoprotein A-1 autoantibodies; SD, 
standard deviation; OD, optical density; HDL, high density lipoprotein; LDL, low density lipoprotein; 
eGFR, estimated Glomerular Filtration Rate. 
* Subjects with positive Anti-ApoA-1 (n=1040) were divided in tertiles (n=347) of increasing titers: 1st 
tertile (0.64<OD<0.77), 2nd tertile (0.77<OD<0.98) and 3rd tertile (OD>0.98). 
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Supplemental Table IV: Baseline characteristics of subjects with vs. without genetic data for the C260T 
rs2569190 polymorphism in the CD14 receptor gene. 
Final sample 
(n=5220) 
Final genotyped sample 
(n=4247) 
Subjects without genetic 
data (n=973) 
p-value 
Age, years 53.4 ± 10.7 48.9 ± 9.9 <0.001 
Male sex, n (%) 2014 (47.0) 482 (48.7) 0.315 
History of CVD, n (%) 342 (8.0) 56 (5.7) 0.013 
Current smoking, n (%) 1106 (25.8) 276 (27.9) 0.173 
Diabetes, n (%) 289 (6.7) 47 (4.8) 0.021 
Hypertension, n (%) 1480 (34.5) 276 (27.9) <0.001 
Body mass index (kg/m2) 25.68 ± 4.42 25.51 ± 4.37 0.273 
Total cholesterol (mmol/l) 5.59 ± 1.03 5.44 ± 0.99 <0.001 
HDL cholesterol (mmol/l)  1.65 ± 0.44 1.60 ± 0.44 0.002 
LDL cholesterol (mmol/l) 3.33 ± 0.91 3.25 ± 0.88 0.013 
Triglycerides (mmol/l) 1.37 ± 1.12 1.37 ± 1.20 0.162* 
SCORE CV risk categories, n (%)    
Low risk 2437 (57.2) 713 (74.7)  
Intermediate risk 1255 (29.5) 174 (18.2)  
High risk 358 (8.4) 36 (3.8)  
Very high risk 208 (4.9) 31 (3.3) <0.001 
Anti-apoA-1 IgG, n (%) 802 (18.81) 238 (24.87) <0.001 
Anti-apoA-1 OD 0.45 ± 0.32 0.51 ± 0.37 <0.001* 
 
Data are expressed as mean ± standard deviation or number of participants and (percentage). CVD, 
cardiovascular disease; SBP, systolic blood pressure; HDL, high density lipoprotein; LDL, low density 
lipoprotein; SCORE, Systematic Coronary Risk Evaluation; Anti-apoA-1 IgG, anti-apolipoprotein A-1 
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autoantibodies; OD, Optical Density. Statistical analysis for continuous variables by student’s t-test or 
Mann-Whitney test (*) depending on the normality assumption. Statistical analysis for categorical 
variables by the chi-squared test. 
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Supplemental Table V: Baseline characteristics of subjects with vs. without genetic data for the C260T 
rs2569190 polymorphism in the CD14 receptor gene or unable to participate in follow up. 
Baseline sample 
(n=6676) 
Final genotyped sample 
(n=4247) 
Subjects without genetic 
data/unable to 
participate in follow-up 
(n=2429) 
p-value 
Age, years 53.4 ± 10.7 51.1 ± 10.6 <0.001 
Male sex, n (%) 2014 (47.0) 1175 (48.1) 0.389 
History of CVD, n (%) 314 (7.3) 144 (5.9) 0.025 
Current smoking, n (%) 1106 (25.8) 706 (28.9) 0.006 
Diabetes, n (%) 289 (6.7) 147 (6.0) 0.243 
Hypertension, n (%) 1480 (34.5) 855 (35.0) 0.706 
Body mass index (kg/m2) 25.7 ± 4.4 26 ± 4.7 0.005 
Total cholesterol (mmol/l) 5.59 ± 1.03 5.55 ± 1.06 0.084 
HDL cholesterol (mmol/l)  1.65 ± 0.44 1.60 ± 0.43 <0.001 
LDL cholesterol (mmol/l) 3.33 ± 0.91 3.32 ± 0.93 0.756 
Triglycerides (mmol/l) 1.37 ± 1.12 1.42 ± 1.27 0.431* 
SCORE CV risk categories, n (%)    
Low risk 2428 (57.2) 1530 (64.3)  
Intermediate risk 1249 (29.4) 595 (25)  
High risk 357 (8.4) 155 (6.5)  
Very high risk 208 (4.9) 101 (4.2) <0.001 
Anti-apoA-1 IgG, n (%) 802 (18.8) 521 (21.8) 0.003 
Anti-apoA-1 OD 0.45 ± 0.32 0.48 ± 0.36 <0.001* 
 
Data are expressed as mean ± standard deviation or number of participants and (percentage). CVD, 
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cardiovascular disease; SBP, systolic blood pressure; HDL, high density lipoprotein; LDL, low density 
lipoprotein; SCORE, Systematic Coronary Risk Evaluation; Anti-apoA-1 IgG, anti-apolipoprotein A-1 
autoantibodies; OD, Optical Density. Statistical analysis for continuous variables by student’s t-test or 
Mann-Whitney test (*) depending on the normality assumption. Statistical analysis for categorical 
variables by the chi-squared test. 
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Supplemental Table VI: Characteristics of the genotyped sample, according to allele status of the 
C260T rs2569190 polymorphism in CD14 receptor gene. 
C260T rs2569190  
allele status 
(CC/CT vs. TT) 
Overall (n=4247) p-value Anti-apoA-1 IgG positive 
subjects (n=798) 
p-value 
CC/CT 
(n=3192) 
TT (n=1055)  CC/CT 
(n=585) 
TT (n=213)  
Age, years 53.5 ± 10.7 53.5 ± 10.9 0.923 53.2 ± 10.7 53.4 ± 11.3 0.835 
Male sex, n (%) 1495 (46.8) 502 (47.6) 0.673 260 (44.4) 108 (50.7) 0.117 
History of CAD, n (%) 122 (3.8) 37 (3.5) 0.640 27 (4.6) 8 (3.8) 0.600 
Current smoking, n 
(%) 
808 (25.3) 282 (26.7) 0.361 153 (26.2) 51 (23.9) 0.527 
Diabetes, n (%) 199 (6.2) 90 (8.5) 0.010 32 (5.5) 15 (7.0) 0.404 
Hypertension, n (%) 1099 (34.4) 371 (35.2) 0.663 203 (34.7) 86 (40.4) 0.140 
Autoimmune disease, 
n (%) 
80 (2.5) 29 (2.8) 0.666 18 (3.1) 11 (5.2) 0.163 
Body mass index 
(kg/m2) 
25.67 ± 
4.46 
25.68 ± 
4.29 
0.973 25.72 ± 
4.67 
25.90 ± 
4.16 
0.622 
Total cholesterol 
(mmol/l) 
5.59 ± 1.03 5.60 ± 1.02 0.715 5.51 ± 1.00 5.55 ± 1.06 0.654 
HDL cholesterol 
(mmol/l)  
1.64 ± 0.44 1.66 ± 0.44 0.501 1.63 ± 0.46 1.65 ± 0.43 0.635 
LDL cholesterol 
(mmol/l) 
3.33 ± 0.91 3.34 ± 0.92 0.753 3.27 ± 0.92 3.31 ± 0.88 0.621 
Triglycerides 
(mmol/l) 
1.38 ± 1.18 1.36 ± 0.93 0.974* 1.39 ± 1.40 1.27 ± 0.81 0.395* 
SCORE CV risk 
categories, n (%) 
      
Low risk 1826 (57.3) 602 (57.1)  346 (59.3) 116 (54.5)  
Intermediate risk 952 (29.9) 297 (28.2)  157 (26.9) 65 (30.5)  
High risk 258 (8.1) 99 (9.4)  53 (9.1) 21 (9.9)  
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Very high risk 151 (4.7) 57 (5.4) 0.379 28 (4.8) 11 (5.2) 0.682 
CV drugs, n (%)       
Aspirin 576 (18.1) 170 (16.1) 0.153 110 (18.8) 29 (13.6) 0.087 
Statins 346 (10.8) 143 (13.6) 0.017 60 (10.3) 22 (10.3) 0.976 
Beta blockers 185 (5.8) 56 (5.3) 0.553 48 (8.2) 13 (6.1) 0.323 
Calcium channel 
blockers 
97 (3.0) 31 (2.9) 0.869 20 (3.4) 5 (2.4) 0.442 
ACEi/ARB 241 (7.6) 83 (7.9) 0.737 43 (7.4) 14 (6.6) 0.706 
Diuretics 63 (2.0) 22 (2.1) 0.822 12 (2.1) 5 (2.4) 0.798 
Anti-apoA-1 IgG, n 
(%) 
585 (18.3) 213 (20.2) 0.179 585 
(100.0) 
213 
(100.0) 
. 
Anti-apoA-1 OD 0.45 ± 0.31 0.45 ± 0.33 0.937* 0.94 ± 0.29 0.93 ± 0.28 0.633* 
Incident CAD, n (%) 100 (3.1) 32 (3.0) 0.872 27 (4.6) 4 (1.9) 0.077 
Non-fatal, n (%) 83 (2.6) 26 (2.5) 0.809 24 (4.1) 4 (1.9) 0.131 
Fatal, n (%) 17 (0.5) 6 (0.6) 0.890 3 (0.5) 0 (0.00) 0.295 
All-cause mortality, n 
(%) 
125 (3.9) 38 (3.6) 0.653 29 (5.0) 13 (6.1) 0.522 
 
Data are expressed as mean ± standard deviation or number of participants and (percentage). Anti-
apoA-1 IgG, anti-apolipoprotein A-1 autoantibodies; CAD, coronary artery disease; HDL, high density 
lipoprotein; LDL, low density lipoprotein; SCORE, Systematic Coronary Risk Evaluation; CV, 
cardiovascular; ACEi, Angiotensin Converting Enzyme inhibitor; ARB, Angiotensin Receptor Blockers; OD, 
optical density. Statistical analysis for continuous variables by student’s t-test or Mann-Whitney test (*) 
depending on the normality assumption. Statistical analysis for continuous variables by the chi-squared 
test. 
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Supplementary Table VII: Hazard Ratios of anti-apoA-1 IgG for incident total, non-fatal and fatal 
CAD according to the C260T rs2569190 polymorphism allele status, in the genotyped population 
Anti-apoA-1 IgG 
HR (95% CI)  
for CAD 
Total Incident CAD (n= 132) Non Fatal Incident CAD (n= 109) Fatal Incident CAD (n= 23) 
C260T rs2569190 
allele status 
Adjusted 
Model_1 
p-
value 
Adjusted 
Model_2 
p-
value 
Adjusted 
Model_1 
p-
value 
Adjusted 
Model_2 
p-
value 
Adjusted 
Model_1 
p-
value 
Adjusted 
Model_2 
p-
value 
CC (n=1097) 2.09 
(0.97–4.47) 
0.058 2.26 (1.04–
4.92) 
0.040 2.13 
(0.95–4.80) 
0.068 2.36 (1.02–
5.42) 
0.044 1.85 
(0.18–18.6) 
0.602 1.52 (0.15–
15.34) 
0.721 
CC/CT (n=3192) 1.73 
(1.10–2.73) 
0.018 1.77 (1.12–
2.80) 
0.014 1.87 
(1.15–3.05) 
0.012 1.96 (1.20–
3.20) 
0.007 0.89 
(0.24–3.25) 
0.858 0.90 (0.24–
3.31) 
0.873 
CT (n=2095) 1.56 
(0.88–2.75) 
0.128 1.50 (0.85–
2.67) 
0.164 1.73 
(0.94–3.20) 
0.081 1.72 (0.92–
3.20) 
0.087 0.59 
(0.11–3.05) 
0.528 0.54 (0.10–
2.93) 
0.475 
TT (n=1055) 0.47 
(0.16–1.36) 
0.163 0.54 (0.18–
1.58) 
0.262 0.59 
(0.20–1.76) 
0.348 0.71 (0.24–
2.12) 
0.536 no subjects  no subjects  
P-value for 
interaction between 
anti-apoA-1 IgG & 
rs2569190 
(CC vs. CT vs. TT) 
 0.015  0.010  0.045  0.029  0.183  n/a 
P-value for 
interaction between 
anti-apoA-1 IgG & 
rs2569190 
(CC/CT vs. TT) 
 0.022  0.025  0.050  0.053  n/a  n/a 
 
Results are expressed as adjusted hazard ratios and (95% confidence interval) for positive 
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(OD>0.64) vs. negative (OD<0.64) anti apoA-1 IgG. Statistical analysis by Cox proportional 
hazards regression adjusted for age, sex, hypertension, diabetes, smoking, HDL cholesterol and 
LDL cholesterol, baseline CAD (Adjusted Model_1), statin and beta-blocker treatment (Adjusted 
Model_2). The P value for interaction represents the likelihood of interaction between the 
C260T rs2569190 allele status and the relative anti-apoA-1 IgG effect for coronary artery 
disease. 
CAD, coronary artery disease; Anti-apoA-1 IgG, anti-apolipoprotein A-1 autoantibodies; HR, 
hazard ratio; CI, confidence interval; OD, optical density; HDL, high density lipoprotein; LDL, low 
density lipoprotein; eGFR, estimated Glomerular Filtration Rate. 
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Supplemental Figure I: Forest plot of subgroup analyses according to the C260T rs2569190 polymorphism allele 
status, for incident total and non-fatal coronary artery disease. 
 
Hazard ratios of anti-apoA-1 IgG (and 95% confidence intervals) are shown for the endpoint of incident total and 
non fatal coronary artery disease, according to C260T rs2569190 polymorphism allele status. Statistical analysis by 
Cox proportional hazards regression adjusted for age, sex, hypertension, diabetes, smoking, HDL and LDL 
cholesterol, baseline CAD, statin, beta-blocker treatment and eGFR. The P value for interaction represents the 
likelihood of interaction between the C260T rs2569190 polymorphism allele status and the relative anti-apoA-1 IgG 
effect for coronary artery disease. 
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Study population and design 14 
We used clinical and biological data from the CoLaus study, a population-based cohort 15 
investigating cardiovascular disease risk in 6733 subjects in the general population aged 35 to 16 
75 and living in the city of Lausanne, Switzerland. The recruitment phase of the study took place 17 
between 2003 and 2006, where all participants attended the outpatient clinic of the University 18 
Hospital of Lausanne. A follow-up visit took place between 2009 and 2012. All study participants 19 
at baseline were invited for a follow-up visit at the outpatient clinic of the University Hospital of 20 
Lausanne, between 2009 and 2012. Subjects unable to attend had home interviews, were 21 
interviewed by phone and/or sent a questionnaire requesting information relevant to study 22 
endpoints. Follow-up data collection started after the baseline visit of each participant. The 23 
study was approved by the Institutional Ethics Committee of the University of Lausanne and 24 
informed consent was obtained from all participants before inclusion in the study, in accordance 25 
with the Declaration of Helsinki. A detailed description of the study design, definition of clinical 26 
variables and sampling procedures have been described elsewhere.1  27 
Briefly, clinical data, and fasting venous blood samples were collected from each participant by 28 
trained field interviewers during a single visit lasting about 60 minutes.  Blood pressure and 29 
heart rate were measured three consecutive times using an automated sphygmomanometer 30 
(Omron® HEM-907, Matsusaka, Japan) and the average of the last two measurements was 31 
used. Body weight and height were measured with participants standing without shoes in light 32 
indoor clothes. Body weight was measured in kilograms to the nearest 100 g using a Seca® 33 
scale, which was calibrated regularly. Height was measured to the nearest 5 mm using a Seca® 34 
height gauge. Body mass index (BMI) was calculated as weight (kg)/height (m2). Hypertension 35 
was defined as a systolic blood pressure (SBP) ≥140 mm Hg and/or a diastolic blood pressure 36 
≥90 mm Hg and/or the presence of anti-hypertensive treatment. Diabetes mellitus was defined 37 
as fasting plasma glucose ≥7.0 mmol/l and/or oral or insulin anti-diabetic treatment. Estimated 38 
glomerular filtration rate (eGFR) was calculated by the simplified “Modification of Diet in Renal 39 
Disease” prediction equation. 2 Autoimmune disease was defined as history of rheumatoid 40 
arthritis or systemic lupus erythematosus, independently of treatment. 41 
Venous blood samples were drawn after an overnight fast, and assays were performed on fresh 42 
plasma samples within two hours after blood collection for standard lipid profile, and on 43 
unthawed serum aliquots for anti-apoA-1 IgG assessment (see below) that were immediately 44 
adequately processed and stored at -80 °C until analysis. 3 Standard lipid profile was performed 45 
in the CHUV Clinical Laboratory using a Modular P apparatus (Roche Diagnostics, Switzerland). 46 
The following analytical procedures (with maximum inter and intra-batch CVs) were used: total 47 
cholesterol by the “CHOD-PAP” method (1.6% – 1.7%); HDL-cholesterol by the “CHOD-48 
PAP/PEG/Cyclodextrin” method (3.6% – 0.9%); triglycerides by the “GPO-PAP” method (2.9% – 49 
1.5%); glucose by glucose dehydrogenase (2.1% – 1.0%); and serum creatinine by the Jaffe 50 
kinetic compensated method (2.9% – 0.7%). 51 
Coronary artery disease and death data collection at baseline and during FU 52 
Trained medical doctors actively searched and collected all medical records related to the 53 
coronary artery disease (CAD, defined as myocardial infarction, stable or unstable angina, 54 
percutaneous coronary revascularization or bypass grafting) in all participants who declared, 55 
during the baseline and/or follow-up interviews, to have presented any cardiac event or 56 
procedure during their lifetime. CAD that occurred during follow-up was classified as incident.  57 
CAD collection in study participants followed a stepwise procedure: 1. The medical record of 58 
each participant was checked by hand with the general practitioner and/or the private 59 
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cardiologist, by both mail surveys and phone interviews. All CAD-related GPs’ reports, reports 60 
on outpatient contacts with medical specialists and hospital discharge reports were copied and 61 
classified. Collected documents further included related laboratory data, electrocardiograms, 62 
cardiac imaging data (echocardiography reports, cardiac radionuclide imaging, magnetic 63 
resonance imaging, cardiac CT, stress tests) and coronary angiograms. 2. To further search for 64 
presence of CAD that may not have been mentioned by the participant during the follow-up visit, 65 
the medical databases of: a. the University Hospital of Lausanne, b. regional hospitals (within a 66 
radius of 100 kilometers), and c. the pre-hospital emergency care unit of the City of Lausanne, 67 
were checked electronically and then also by hand for CAD-related diagnoses, for all study 68 
participants.  69 
Data on deceased study participants were likewise collected in a stepwise procedure, by 70 
checking electronically and then also by hand the electronic databases of: a. the University 71 
Hospital of Lausanne, b. regional hospitals (within a radius of 100 kilometers), c. population 72 
registers of the cities where the participants were living in case of returned mail and/or multiple 73 
unsuccessful phone contacts, d. the pre-hospital emergency care unit of the City of Lausanne, 74 
e. the forensic medicine department of the University Hospital of Lausanne, and f. the “Office 75 
Fédérale de la Statistique”, the Swiss governmental agency providing death statistics. If a death 76 
was confirmed, physicians of the dead participants were asked to send any medical record 77 
related to the death. If all previous steps failed to retrieve the cause of death, the physician in 78 
charge when the death occurred and/or a family member of the dead participant were contacted 79 
to provide information on the cause of death (verbal autopsy). 80 
 81 
Study Endpoints 82 
The primary endpoint was total incident CAD as defined by a composite of first-time, fatal or 83 
non-fatal myocardial infarction, stable or unstable angina, percutaneous coronary 84 
revascularization or bypass grafting for CAD. Separate outcomes of interest included non-fatal 85 
as well fatal CAD (definite or probable, in-hospital or out-of-hospital). 4 All CAD events were 86 
adjudicated separately by two cardiologists, blinded to all study variables, according to a 87 
consensus document edited on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the 88 
“Universal Definition of Myocardial Infarction”. 5 All deaths were adjudicated, by 2 internal 89 
medicine specialists.  90 
In subjects with available genetic data for the functional C260T rs2569190 polymorphism in the 91 
CD14 receptor gene, the secondary study outcome was to test the interaction between anti-92 
apoA-1 IgG and carriage of the T allele, with regards to incident CAD.  93 
 94 
Assessment of anti-apoA-1 IgG levels 95 
Anti-apoA-1 IgG were measured as previously described, 6-8 using the CoLaus study (2003-96 
2006) frozen serum aliquots, stored at -80 °C. Maxisorp plates (NuncTM, Denmark) were coated 97 
with purified, human-derived delipidated apolipoprotein A-1 (20 μg/ml; 50 μl/well) for 1h at 37°C. 98 
After being washed, all wells were blocked for 1h with 2% bovine serum albumin (BSA) in a 99 
phosphate buffer solution (PBS) at 37°C. Participants’ samples were also added to a non-100 
coated well to assess individual non-specific binding. After six washing cycles, a 50 μl/well of 101 
signal antibody (alkaline phosphatase-conjugated anti-human IgG; Sigma-Aldrich, St Louis, 102 
MO), diluted 1:1000 in a PBS/BSA 2% solution, was added and incubated for 1h at 37°C. After 103 
washing six more times, phosphatase substrate p-nitrophanylphosphate disodium (Sigma-104 
Aldrich) dissolved in a diethanolamine buffer (pH 9.8) was added and incubated for 20 min at 105 
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37°C (Molecular DevicesTM Versa Max). As previously published, this assay detects anti-apoA-1 106 
antibodies directed against the native lipid-free apoA-1. 9, 10 Optical density (OD) was 107 
determined at 405 nm, and each sample was tested in duplicate. Corresponding non-specific 108 
binding was subtracted from mean OD for each sample. The specificity of detection was 109 
assessed using conventional saturation tests by Western blot (WB) analysis.   110 
As previously described, elevated levels of anti-apoA-1 IgG were set at an OD cut-off of 111 
OD>0.64, corresponding to the 97.5th percentile of a reference population. 6-8 In order to limit the 112 
impact of inter-assay variation, we further calculated an index consisting in the ratio between 113 
sample net absorbance and the positive control net absorbance × 100. The index value 114 
corresponding to the 97.5th percentile of the normal distribution was 37. Accordingly, to be 115 
considered as positive (presenting elevated anti-apoA-1 IgG levels), samples had to display 116 
both an absorbance value >0.64 OD and an index value ≥37%. 117 
As described before, 9, 10 our ELISA principally detects immunoreactivity (anti-apoA-1 IgG) 118 
against unmodified form of apoA-1. In order to further determine whether our assay is 119 
specifically dedicated to detect antibodies against native apoA-1 devoid of post-translational 120 
modifications (PTM) and does not cross-react with other forms of modified apoA-1, we used our 121 
human purified apoA-1 to generate carbamylated apoA-1, glycated apoA-1, and oxidized apoA-122 
1 to be tested as coating antigen in our ELISA, comparing the respective signals produced by 123 
Passing-Bablock analyses. 124 
ApoA-1 carbamylation was performed according to the protocol by Holzer et al. 11 Briefly, native 125 
human purified ApoA-1 was carbamylated with potassium cyanate (50 mmol/L) in phosphate 126 
buffered saline (pH 7.4) containing 100 µmol/L diethylenetriaminepentaacetic acid (DTPA) for 4 127 
hours at 37°C. As a control, the same protocol was applied in the absence of potassium 128 
cyanate. All preparations were passed through a column (MWCO 10,000 Da) to remove excess 129 
reagents and used immediately for experiments. The apoA-1 carbamylation state was then 130 
verified using commercial ELISA (OxiSelect Protein Carbamylation Sandwich Elisa kit from Cell 131 
Biolabs; ref. STA-877). The quantity of carbamylated apoA-1 generated by this protocol was 132 
33.8 ng/ml against 2.9 ng/ml with the control procedure. 133 
 134 
ApoA-1 glycation was performed according to the protocol by Nobécourt et al. 12 Briefly, native 135 
human purified apoA-1 was exposed to methylglyoxal (MG) (6mmol/l) in phosphate buffered 136 
saline containing 100 µmol/L etilendiaminotetracetic acid (EDTA) for 24 hours at 37°C under 5% 137 
CO2. As a control, the same protocol was applied in the absence of MG. All preparations were 138 
passed through a column (MWCO 10,000 Da) to remove excess reagents and used 139 
immediately for experiments. The apoA-1 glycation state was then verified using commercial 140 
ELISA (OxiSelect Methylglyoxal Competitive Elisa kit; Cell Biolabs ref. STA-811). The quantity 141 
of MG glycated apoA-1 generated with this protocol was 138.9µg/ml against 0.07 µg/ml with the 142 
control procedure. 143 
ApoA-1 oxidation was performed according to the protocol by DiDonato et al. 13 Briefly, native 144 
human purified apoA-1 was oxidized in 60 mmol/l Na[PO4] buffer (pH 7.4) using CuSO4 145 
(10µmol/l) with 40 µmol/l of H2O2 for 24 hours at 37°C. As a control, the same protocol was 146 
applied in the absence of CuSO4 and H2O2. All preparations were passed through a column 147 
(MWCO 10,000 Da) to remove excess reagents and used immediately for experiments. The 148 
amount of apoA-1 oxidation state was first verified by the mobility shift on SDS-PAGE gels, and 149 
visualized by WB. As shown in Supplemental Figure II, the expected higher MW apoA-1 150 
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bands induced by oxidation-mediated apoA-1 dimers formation were achieved by combining 151 
H202 and CuS04, allowing to use this procedure to generate oxidized apoA-1 for further 152 
experiments.  153 
These results indicate that i) our in vitro procedure generated the expected PTM, and that ii) the 154 
native apoA-1 used in the present study does not contain substantial amount of carbamylation, 155 
glycation or oxidation.  156 
In order to further explore a theoretical potential influence of carbamylation, glycation or 157 
oxidation of apoA-1 in our study, we further performed Passing-Bablock analyses using 158 
carbamylated, glycated, oxidized apoA-1. Using these modified forms of apoA-1 in our in house 159 
ELISA assay, we compared the immunoreactivity signals obtained, with those derived using 160 
native apoA-1 on a subset of n=63 randomly selected Colaus subjects and displaying a anti-161 
apoA-1 IgG positivity rate of 17% (11/63), closely corresponding to the anti-apoA-1 IgG positivity 162 
rate retrieved on the whole CoLaus cohort (19%). 163 
As shown in Supplemental Figure III, using carbamylated apoA-1 as coating antigen in our 164 
ELISA induced a significant proportional bias of + 22% (slope: 1.22; 95%CI: 1.13-1.33), but no 165 
systematic bias (intercept:-0.004; 95%CI:-0.04-0.04). Indeed, taking the same anti-apoA-1 IgG 166 
positivity definition, using carbamylated apoA-1 induced a positivity rate of 27% with n=7 167 
discordant cases. Six were false positives ((FP): samples that were negative when using native 168 
apoA-1) and one was false negative ((FN): sample that was tested positive using native apoA-169 
1), translating into a significant anti-apoA-1 IgG positivity rate discordance of 64% (0/11 vs. 170 
7/11; p=0.003). These results indicate that using carbamylated apoA-1 provides a significant 171 
different signal than using native apoA-1 in our ELISA. 172 
As shown in the Supplemental Figure IV, using glycated apoA-1 as coating antigen in our 173 
ELISA, induced a non-significant proportional positive bias of + 8% (slope: 1.08,95%CI:0.97-174 
1.24), and a small statistically significant, but minor bias of 0.07 arbitrary units (Intercept: -0.07; 175 
95%CI:-13 to -0.02). These results indicate that our ELISA is insensitive to apoA-1 MG-induced 176 
glycation status. 177 
Lastly, as depicted in Supplemental Figure V, using oxidized apoA-1 as coating antigen in our 178 
ELISA showed that the two methods provide identical results with a no proportional bias (slope: 179 
1.003; 95%CI:0.82-1.34) and no systematic bias (intercept :-0.0006; 95%CI:-0.09-0.09) when 180 
compared to using human purified native apoA-1. These results indicate that our ELISA is 181 
insensitive to apoA-1 oxidation status. 182 
Lastly, in order to further eliminate the possibility of anti-apoA-1 IgG being directed against 183 
glycated, carbamylated, oxidized apoA-1 or PTM-induced cross-linked multimers of apoA-1, we 184 
adapted our ELISA protocol, performing additional WB and Liquid Chromatography (LC) – Mass 185 
Spectrometry (MS)/MS analyses on pooled serum derived from n=3 study patients tested 186 
positive and n=3 tested negative for anti-apoA-1 IgG.  187 
For the WB analysis, one microgram of purified delipidated apoA-1 devoid of PTM was resolved 188 
by 10% polyacrylamide gel electrophoresis under reducing conditions and transferred to a 189 
polyvinylidene difluoride (PVDF) membrane (Immobilon, Millipore IPVH 00010), which was then 190 
blocked for 1 hour at RT with non-fat dry milk 5% in tris-buffered saline with tween 20 (T-TBS). 191 
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Membranes were incubated with pooled sera derived from three anti-apoA-1 IgG positive 192 
(OD405nm value: 1.7 AU) patients and three anti-apoA-1 IgG negative patients (OD405nm value: 193 
0.2 AU) diluted (1:50) in non-fat dry milk 5% in T-TBS 2 hours at room temperature. A goat anti-194 
human IgG or rabbit anti-goat horseradish peroxidase conjugated (Dako, Agilent) was used as 195 
secondary antibody, diluted 1:7000 in non-fat dry milk 5% in T-TBS for 1 hour at room 196 
temperature. The detection was performed using the BM Chemiluminescence Blotting Substrate 197 
(POD from Roche). The blot was exposed to horseradish peroxidase-conjugated anti-human Fc 198 
IgG to reveal the anti-apoA-1 IgG binding and with horseradish peroxidase-conjugated anti-goat 199 
Fc IgG for the commercially available goat anti-human apoA-1 IgG used as positive control. 200 
As shown in Supplemental Figure VI, pooled sera from the anti-apoA-1 IgG positive patients 201 
displayed a strong signal at 61 kD (panel A), whereas sera derived from anti-apoA-1 IgG 202 
negative patients hardly provided a signal on WB (panel B). Polyclonal goat anti-human apoA-1 203 
IgG displayed the expected 29kD MW band (panel C), as well as the one at 61 KD, in 204 
accordance to our previous experiments. 9  205 
We then submitted the identified 61kD MW band to LC-MS/MS analyses. According to our in-gel 206 
digestion protocol, gel pieces were dehydrated with 100 μl of 50 mM ammonium bicarbonate 207 
(AB) in 30% acetonitrile (ACN) for 10 min. This solution was removed and gel pieces were then 208 
incubated for 35 minutes at 56°C in 100 μl of 10 mM DTT in 50 mM AB. DTT solution was then 209 
replaced by 100 μl of 55 mM iodoacetamide in 50 mM AB and the gel pieces were incubated for 210 
30 min at room temperature in the dark. Gel pieces were then washed for 30 minutes with 100 211 
μl of 50mM AB and for 30 min with 100 μl of 50 mM AB and 30% ACN. Gel pieces were then 212 
dried for 45 minutes in a Speed-Vac Concentrator. Dried pieces of gel were rehydrated for 45 213 
minutes at 4°C in 50 μl of a solution of 50 mM AB containing trypsin at 6.25 ng/μl. Extraction of 214 
the peptides was performed with 50 μl of 1% trifluoroacetic acid (TFA) for 30 minutes at room 215 
temperature with occasional shaking. The TFA solution containing the proteins was transferred 216 
to a polypropylene tube. A second extraction of the peptides was performed with 70 μl of 0.1% 217 
TFA in 50% ACN for 30 minutes at room temperature with occasional shaking. The second TFA 218 
solution was pooled with the first one. The pooled extracts were completely dried by evaporation 219 
under speed-vacuum. LC-ESI-MS/MS was performed on a Orbitrap XL Mass Spectrometer 220 
(Thermo Fisher Scientific) equipped with a NanoAcquity system from Waters. Peptides were 221 
trapped on a home-made 5 µm 200 Å Magic C18 AQ (Michrom) 0.1 × 20 mm pre-column and 222 
separated on a home-made 5 µm 100 Å Magic C18 AQ (Michrom) 0.75 × 150 mm column with 223 
a gravity-pulled emitter. The analytical separation was run for 40 minutes using a gradient of 224 
H2O/FA 99.9%/0.1% (solvent A) and CH3CN/FA 99.9%/0.1% (solvent B) from 5% to 35% A in 225 
20 minutes at a flow rate of 220 nL/min. For MS survey scans, the OT resolution was set to 226 
60000 and the ion population was set to 5 × 105 with an m/z window from 400 to 2000. Four 227 
precursor ions were selected for collision-induced dissociation (CID) in the LTQ. For this, the ion 228 
population was set to 1 × 104 (isolation width of 2 m/z). The normalized collision energies were 229 
set to 35% for CID. Then, for protein identification, peak lists (MGF file format) were generated 230 
from raw data using the MS Convert conversion tool from ProteoWizard The peaklist files were 231 
searched against the Homo sapiens database (UniProtKB, release 2017-03, 20184 entries) 232 
using Mascot (Matrix Science, London, UK; version 2.5.1). Trypsin was selected as the enzyme, 233 
with two potential missed cleavage sites. Precursor ion tolerance was set to 10 ppm and 234 
fragment ion tolerance to 0.6 Da. Variable amino acid modifications were oxidized methionine, 235 
carbamylated lysine, and glycated lysine, arginine and tryptophan. Fixed amino acid 236 
modification was carbamidomethyl cysteine. The Mascot search was validated using Scaffold 237 
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4.7.5 (Proteome Software). Protein identifications were accepted if they could be established at 238 
greater than 95.0 % probability and contained at least two identified peptides. 239 
Results are shown in Supplemental Figure VII. Analysis of this 61 kD band identified apoA-1 240 
with a total of 29 identified peptides spectrum matched (PSM), corresponding to 12 unique 241 
peptide sequences, representing a protein sequence coverage of 47% (highlighted in yellow). 242 
Among these 29 PSM, 3 PSM with the same sequence ((K)WQEE Mox ELYR(Q)) were 243 
identified with an oxidized methionine (Supplemental Figure VII, red frame). The amount of 244 
oxidation could not be quantified exactly using this LC-MS/MS system, but as only one oxidized 245 
methionin was found, the oxidation status of apoA-1 is likely to be insignificant and most 246 
probably generated by the WB and LC-MS/MS process given apoA-1 susceptibility to oxidation. 247 
Moreover, among these 29 PSM, no carbamylation or glycation were detected. Of interest, 8 of 248 
these PSM corresponded to the C-terminal sequence spanning aa 240 to 265 (data not shown). 249 
On this C-terminal sequence no oxidation or other PTM were identified.  250 
These WB & LC-MS/MS findings indicate that the apoA-1 band at 61 KD recognized on WB by 251 
pool sera derived from patients tested positive for anti-apoA-1 IgG is very unlikely to result from 252 
recognition of glycated, carbamylated, oxidized cross-linked multimers of apoA-1. The most 253 
likely explanation for this phenomenon is that anti-apoA-1 IgG preferentially recognize lipid-low 254 
apoA-1. However, as the lipid content of our apoA-1 preparation is not assessable by LC-255 
MS/MS, this hypothesis warrants further study. 256 
Taken together, these supplementary characterization analyses point to two main conclusions. 257 
The first one is that our native human purified apoA-1 does not contain substantial amount of 258 
carbamylation, glycation or oxidation, confirming previous studies that demonstrate that the 259 
immune response to apoA-1 measured in our assay is well directed against unmodified apoA-1, 260 
devoid of PTM. 9, 10 The second one is that that our assay is not significantly influenced by 261 
glycation or oxidation of apoA-1.  262 
Genotyping of the C260T rs2569190 polymorphism in the CD14 receptor gene. 263 
After exclusion of non-Caucasian participants (n=395) and those with missing genetic data 264 
(n=578), the final genotyped sample for the C260T rs2569190 polymorphism consisted of 4247 265 
individuals (Figure 1). Genotyping was performed using the Affymetrix GeneChip Human 266 
Mapping 500K array set, excluding SNPs with call rate <70% and individuals with call rate 267 
<90%. The imputation dataset included 390,631 genotyped SNPs with call rate>0.9, Hardy–268 
Weinberg P-value>10-7 and minor-allele frequency (MAF)>1%. Imputation was performed using 269 
IMPUTE version 0.2.0 and CEU haplotypes from HapMap release 21. The C260T rs2569190 270 
polymorphism was imputed with an r2-hat=0.994. The minor allele in the CoLaus study was T 271 
(49.3%) and the major allele C (50.7%), which is consistent with previous reports in Caucasian 272 
populations. 14 273 
 274 
Statistical analyses 275 
Univariate analysis of continuous variables was performed using the student’s t-test or the non-276 
parametric Mann-Whitney test as appropriate, and results were expressed as mean ± standard 277 
deviation (SD). Analysis of discrete variables was performed using chi-square test and results 278 
were expressed as number of participants and (percentage). Survival curves for incident CAD 279 
were produced using the Kaplan-Meier method and compared using the Logrank test. Patients 280 
who had no events were censored at the time of death, loss to follow-up or the end of the study 281 
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period. Multivariate analysis of the associations between anti-apoA-1 IgG and incident CAD was 282 
performed using Cox proportional hazards adjusting for sex, age, smoking status, diabetes, 283 
hypertension, low (LDL) and high density lipoprotein cholesterol (HDL), baseline CAD, statin 284 
and beta-blocker treatment and eGFR. Results were expressed as hazards ratio (HR) and 95% 285 
confidence interval (CI). Adjusted HRs for incident CAD were firstly estimated for anti-apoA-1 286 
IgG positivity as well as across tertiles of increasing anti-apoA-1 IgG values, with anti-apoA-1 287 
IgG negative subjects used as the reference group. As anti-apoA-1 IgG concentration 288 
distribution is skewed, values were further natural log transformed and standardized (mean=0 289 
and SD=1) and HR for incident CAD were also assessed per one SD change. The same 290 
analyses were repeated in genotyped subjects according to CD14 SNP subgroups and a 291 
statistical interaction test was performed to assess differences between these genotype 292 
subgroups. 15 Sensitivity analyses were performed after exclusion of subjects with baseline CAD 293 
and autoimmune disease. 294 
In genotyped subjects, we first assumed an additive model (CC vs. CT vs. TT), dividing the 295 
sample into three subgroups according to the C260T rs2569190 allele status. As previously 296 
suggested, 14, 16 we then assumed a recessive model (CC/CT vs. TT), where C-allele carriers 297 
show similar, neutral CD14 gene expression, while homozygotes for the minor allele present 298 
increased CD14 gene expression. 17, 18 In both cases, a statistical interaction test was performed 299 
to assess the heterogeneity of anti-apoA-1 IgG-related CAD risk, according to carriage of the T 300 
allele. 15 Results were expressed as HR (95%CI) within each subgroup and presented as a 301 
forest plot. 15 Taking into account the incident CAD rate in CoLaus (157 events or 3%) and a 302 
two-sided alpha of 5%, we required 35-59 incident CAD events in subjects positive for anti-303 
apoA-1 IgG to detect an HR of anti-apoA-1 IgG for CAD of 1.5-1.7 with >80% power. Similarly, 304 
considering the incident nonfatal CAD rate of 2.5% in our study and two-sided alpha of 5%, we 305 
required 32-55 incident non-fatal CAD events in subjects positive for anti-apoA-1 IgG to detect 306 
an HR of 1.5-1.7 with >80% power. All analyses were performed using STATA 13.0 (Stata Corp, 307 
College Station, Texas, USA). A two-tailed test with p<0.05 was considered statistically 308 
significant. 309 
 310 
 311 
 312 
 313 
 314 
315 
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FIGURES 316 
 317 
 318 
Figure 1. ApoA-1 oxidation Western Blot. Panel A) one-second exposition, B) two-minutes exposition in 319 
order to visualize the oxidation-induced apoA-1 dimerization. The expected higher molecular weight 320 
apoA-1 bands induced by oxidation-mediated apoA-1 dimers formation were achieved by combining 321 
H202 and CuS04. 322 
323 
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 324 
 325 
Figure 2. Passing-Bablock analysis comparing the signals obtained using native versus carbamylated 326 
apoA-1. The grey line indicates the identity line, the red line indicates the correlation obtained. Using 327 
carbamylated apoA-1 as coating antigen in our ELISA, induced a significant proportional bias of + 22% 328 
(slope: 1.22; 95%CI: 1.13-1.33), but no systematic bias (intercept: -0.004; 95%CI: -0.04-0.04).  329 
330 
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 331 
 332 
Figure 3. Passing-Bablock analysis comparing the signals obtained using native versus glycated apoA-1. 333 
The grey line indicates the identity line, the red line indicates the correlation obtained. Using glycated 334 
apoA-1 as coating antigen in our ELISA, induced a non-significant proportional positive bias of + 8% 335 
(slope: 1.08; 95%CI: 0.97-1.24), and a small statistically significant, but minor bias of 0.07 arbitrary units 336 
(Intercept: -0.07; 95%CI: -13 to -0.02). 337 
338 
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 339 
 340 
Figure 4. Passing-Bablock analysis comparing the signals obtained using native versus oxidized apoA-1. 341 
The grey line indicates the identity line, the red line indicates the correlation obtained. Using oxidized 342 
apoA-1 as coating antigen in our ELISA, induced a non significant proportional bias of 0.3% (slope: 1.003; 343 
95%CI: 0.82-1.34) and no systematic bias (intercept: -0.0006; 95%CI:-0.09-0.09). 344 
345 
  
13 
 346 
 347 
Figure 5. Western blot of anti-apoA-1 IgG. Human apoA-1 was migrated on polyacrylamide gel (10%) 348 
and then exposed to pooled sera (dilution 1:50) of patients tested either positive (panel A) or negative 349 
for anti-apoA-1 IgG (panel B). The sera from the anti-apoA-1 IgG positive patients displayed a strong 350 
signal at 61 kD (panel A), whereas the pooled sera derived from anti-apoA-1 IgG negative patients hardly 351 
provided a signal on WB (panel B). Polyclonal goat anti-human apoA-1 IgG displayed the expected 29kD 352 
molecular weight band (panel C), as well as a band at 61 KD, further submitted to liquid chromatography 353 
– mass spectrometry analyses. 354 
355 
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 356 
 357 
 358 
Figure 6. Liquid Chromatography – Mass Spectrometry Analyses of the 61kD apoA-1 band. Above : 359 
Highlighted in yellow the 12 exclusive amino acid sequences identified in the 61kD apoA-1 band. 360 
Highlighted in green, the only oxidized methionin found. Below : Among the 29 peptides spectrum 361 
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matched (PSM), 3 PSM with the same sequence ((K)WQEE Mox ELYR(Q)) were identified with an oxidized 362 
methionine (sequences in the red frame), but no carbamylation or glycation were detected.  363 
364 
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